Optimizing Early Breast Cancer Outcomes in the Community Setting: An Expert Review of Emerging Therapies and Evolving Standards of Care in HR+/HER2- Disease

September 28, 2022

Target Audience

Community medical oncologists, oncology advanced practice providers (NPs, PAs,) oncology pharmacists, oncology nurses, and other members of the community-based interprofessional, multidisciplinary breast cancer care team.

Learning Objectives

  • Review the epidemiology and clinical characteristics of HR+, HER2- early-breast cancer (EBC), and identify patients at an elevated risk of disease recurrence as a means of guiding treatment.
  • Appraise the current treatment landscape in HR+, HER2- EBC, including the established and emerging evidentiary base for novel therapies in the adjuvant setting, expert consensus guidelines, and FDA-approved indications.
  • Recognize treatment-related adverse events associated with oral therapies used in HR+, HER2- EBC and implement evidence-supported mitigation and management protocols.
  • Using real-world patient case examples, design on-label treatment plans for HR+, HER2- EBC at high risk for recurrence, emphasizing the critical need for effective communication and coordination strategies among the multidisciplinary community-based breast cancer care team.
  • Evaluate adaptive approaches for promoting adherence and persistence to oral anticancer therapies, highlighting common reasons for noncompliance and the impact of patient counseling and shared decision-making (SDM).

Presented by Creative Educational Concepts, LLC.

Supported through an independent educational grant from Lilly.

Additional Information

AttachmentSize
PDF icon General Information170.34 KB
PDF icon Handout and References1.85 MB
Course summary
Available credit: 
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 ICPE
  • 1.00 Participation
Course opens: 
09/15/2022
Course expires: 
10/28/2022
Event starts: 
09/28/2022 - 12:00pm EDT
Event ends: 
09/28/2022 - 1:00pm EDT

  5 min: Welcome and Introductions

10 min: Fundamental Foundations in Early Breast Cancer: Epidemiology, Clinical Features, and Stratifying Recurrence Risk

15 min: The State of the HR+, HER2- EBC Paradigm: Approved Indications, Expert Guidelines, and Toxicity Management

20 min: Multidisciplinary Momentum: Real-World EBC Perspectives for the Community-Based Breast Cancer Care Team

10 min: Conclusion and Interactive Audience Q&A

Community Grand Rounds
United States

Sara Tolaney, MD, MPH
Chief, Division of Breast Oncology
Associate Director, Susan F. Smith Center for Women’s Cancers
Dana-Farber Cancer Institute
Associate Professor of Medicine, Harvard Medical School
Boston, MA


 


It is the policy of Creative Educational Concepts, LLC, (CEC) to ensure independence, balance, objectivity, and scientific rigor and integrity in all their CME/CE activities. Activity planners, faculty, peer reviewers, and CEC staff must disclose to the participants any relationships with ineligible entities whose products or devices may be mentioned in this CE activity, or with the commercial supporter of this CE activity. An ineligible entity is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Financial relationships may include research grants, consultant fees, travel, advisory boards, consultancy, speakers’ bureaus, other benefits, or having a self-managed equity interest in a company.

CEC has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Planners:
Elizabeth Dow-Hillgartner, PharmD, BCPS, BCOP–has no relevant financial relationships to disclose in relation to the content of this activity.
Jennifer A. McKenna, NP–has no relevant financial relationships to disclose in relation to the content of this activity.
Sara Tolaney, MD, MPH–has disclosed that she is a consultant for 4D Pharm, AstraZeneca, Athenex, Bristol-Myers Squibb, BeyondSpring Pharmaceuticals, Certara, Chugai Pharmaceuticals, CytomX, Daiichi Sankyo, Eisai, Eli Lilly, Ellipses Pharma, Genentech/Roche, Immunomedics/Gilead, Merck, Mersana Therapeutics, Nanostring, Nektar, Novartis, Odonate, OncoSec Medical Incorporated, Pfizer, Puma, Sanofi, and Seattle Genetics. She receives grant/research funding from Bristol-Myers Squibb, Cyclacel, Eisai, Eli Lilly, Exelixis, Genentech/Roche, Immunomedics/Gilead, Merck, Nanostring, Nektar, Novartis, Odonate, Pfizer, Sanofi, and Seattle Genetics.

Presenters:
Elizabeth Dow-Hillgartner, PharmD, BCPS, BCOP–has no relevant financial relationships to disclose in relation to the content of this activity.
Hope S. Rugo, MD–has disclosed that she receives grant/research support from AstraZeneca, Ayala, Astellas, Boehringer Ingelheim, Daiichi, Gilead, Lilly, Macrogenics, Merck, Novartis, Pfizer, Polyphor, Roche, and Seattle Genetics.
Sara Tolaney, MD, MPH–has disclosed that she is a consultant for 4D Pharm, AstraZeneca, Athenex, Bristol-Myers Squibb, BeyondSpring Pharmaceuticals, Certara, Chugai Pharmaceuticals, CytomX, Daiichi Sankyo, Eisai, Eli Lilly, Ellipses Pharma, Genentech/Roche, Immunomedics/Gilead, Merck, Mersana Therapeutics, Nanostring, Nektar, Novartis, Odonate, OncoSec Medical Incorporated, Pfizer, Puma, Sanofi, and Seattle Genetics. She receives grant/research funding from Bristol-Myers Squibb, Cyclacel, Eisai, Eli Lilly, Exelixis, Genentech/Roche, Immunomedics/Gilead, Merck, Nanostring, Nektar, Novartis, Odonate, Pfizer, Sanofi, and Seattle Genetics.

Peer Reviewer:
Katherine Lee, PharmD, MPH–has no relevant financial relationships to disclose in relation to the content of this activity.

CEC Staff:
Bryan C. Taylor, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Ashley C. Lilly, MHA–has no relevant financial relationships to disclose in relation to the content of this activity.

Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CEC, the faculty, and any commercial supporter of this activity do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

 

This activity was planned by and for the healthcare team, and learners will receive 1 hour of Interprofessional Continuing Education (IPCE) credit for learning and change.

 

Medicine (ACCME)
CEC designates this live educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacy (ACPE)
This application-based activity is approved for 1.0 contact hour (.10 CEUs) of continuing pharmacy education credit (JA0007101-0000-22-020-L01-P)

Nursing (ANCC)
This activity is designated for 1.0 contact hour.

Upon completion of a CE request form, statements of credit for physicians, physician assistants, and nurses will be issued within 30 business days. Pharmacy credit will be reported directly to the National Association of Boards of Pharmacy® (NABP®) CPE Monitor electronic CE tracking system.

Available Credit

  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 ICPE
  • 1.00 Participation
Please login or register to take this course.